Skip to main content
Blog Post | Competition Chronicle

Antitrust Issues in Canadian Private Equity

Fasken
Reading Time 1 minute read
Subscribe
Share
  • LinkedIn

Overview

What antitrust scrutiny can U.S. private equity expect in Canada? 

Numerous recent proceedings by the U.S. Federal Trade Commission and Department of Justice have made antitrust issues top of mind for U.S. private equity (PE). 

Given the frequent investment by U.S. sponsors into Canada, it is prudent to query whether a similar increase in regulatory scrutiny of PE is occurring north of the border.

The short answer is yes, and several examples are illustrative.

Writing in the ABA’s M&A Deal Points, we review these precedents for the benefit of U.S. PE considering a Canadian acquisition or minority investment.

We also consider certain differences between U.S. and Canadian antitrust law, as well as the practical impacts greater regulatory oversight of PE by Canadian competition authorities is having on risk mitigation and deal dynamics.

Contact the Authors

For more information or to discuss a particular matter please contact us.

Contact the Authors

Authors

  • Caitlin Rose, Partner | Co-Leader, Private Equity, Montréal, QC, +1 514 397 5277, crose@fasken.com
  • Grant E. McGlaughlin, Partner | Co-Leader, Private Equity, Toronto, ON, +1 416 865 4382, gmcglaughlin@fasken.com
  • Paul Blyschak, Counsel | Corporate/Commercial, Calgary, AB, +1 403 261 9465, pblyschak@fasken.com

    Subscribe

    Receive email updates from our team

    Subscribe